RxDoctor Payments DataLook up a doctor →

Maha Assi, MD

Infectious Disease · Wichita, KSNPI 1922071224

Payments from drug & device makers

$204,390in general payments, 2019–2025

Across 279 payments — averaging $732.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ADMA Biomanufacturing LLC$151K
  • Octapharma USA, Inc.$25K
  • Mannkind Corporation$13K
  • Ferring Pharmaceuticals AS$8K
  • AbbVie$4K
  • Ferring Pharmaceuticals Inc.$2K
  • plus $2K from 20 others
$170,014in research payments, 2019–2025

Across 184 payments — averaging $923.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • ADMA Biomanufacturing LLC$170K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$204,390 in reported general payments places this provider in the 95th percentile of 56 infectious disease providers in Kansas.

See all infectious disease providers in Kansas

Medicare billing

Part B allowed, 2024
$769,012
Medicare patients
670
Services billed
77,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →